Toronto, Ontario–(Newsfile Corp. – November 12, 2020) – Eric Sprott announces that he beneficially owns and controls 3,200,000 common shares (shares) and 1,100,000 share purchase warrants (warrants) of Entheon Biomedical Corp., representing approximately 7.9% on a non-diluted basis of the outstanding shares and 10.4% on a partially diluted basis, assuming the exercise of such warrants.
Mr. Sprott understands that Entheon Biomedical Corp. has commencing trading on the Canadian Securities Exchange effective November 12, 2020 under the symbol “ENBI”, following a business combination with Entheon Holdings Corp. (formerly Entheon Biomedical Corp.), as further described in Entheon Biomedical’s press release dated November 5, 2020.
The securities owned by Mr. Sprott through the business combination are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities of Entheon Biomedical including on the open market or through private acquisitions or sell securities of Entheon Biomedical including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.
Entheon Biomedical is located at 10th Floor, 595 Howe Street, Vancouver, British Columbia, V6C 2T5. A copy of the early warning report with respect to the foregoing will appear on the company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com and may also be obtained by calling Mr. Sprott’s office at (416) 945-3294 (200 Bay Street, Suite 2600, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J1).
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68115